2026-06-14T00:44:37Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/179252024-02-10T20:02:24Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Godoy-Ortiz, Ana author Sanchez-Muñoz, Alfonso author Chica Parrado, Maria Rosario author Álvarez, Martina author Ribelles, Nuria author Rueda Dominguez, Antonio author Alba, Emilio author 2019-10-29 The main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer progression, creating a significant variability within primary tumors as well as between the primary breast cancer and their metastases, a hypothesis have already demonstrated in retrospective studies (1). A clear example of this is the HER2-positive breast cancer. In these tumors, we can find all of the transcriptional subtypes of breast cancer, even the basal like or luminal A subtypes. Although the HER2-enriched is the most representative transcriptional subtype in the HER2-positive breast cancer, we can find it too in breast cancers with HER2-negative status. This intrinsic subtype shows a high expression of the HER2 and is associated with proliferation-related genes clusters, among other features. Therefore, two hypotheses can be suggested. First, the HER2 amplification can be a well-defined driver event present in all of the intrinsic subtypes, and not a subtype marker isolated. Secondly, HER2-enriched subtype can have a distinctive transcriptional landscape independent of HER2 amplification. In this review, we present an extensive revision about the last highlights and advances in clinical and genomic settings of the HER2-positive breast cancer and the HER2-enriched subtype, in an attempt to improving the knowledge of the underlying biology of both entities and to explaining the intrinsic heterogeneity of HER2-positive breast cancers. 10.3389/fonc.2019.01124 2234-943X Frontiers in oncology http://hdl.handle.net/10668/14703 31737566 http://hdl.handle.net/20.500.12105/17925 HER2-enriched HER2-positive Breast cancer Heterogeneity Intrinsic subtype Molecular Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.